Neuropeptidni Y receptor

Pankreasni polipeptidni receptor 1
Pankreasni polipeptidni receptor 1
Identifikatori
Simbol	PPYR1
Alt. simboli	NPY4R, Y4, PP1
Entrez	5540
HUGO	9329
OMIM	601790
RefSeq	NM_005972
UniProt	P50391
Ostali podaci
Lokus	Hromozom 10 q11.2

Neuropeptidni Y receptor Y2
Neuropeptidni Y receptor Y2
Identifikatori
Simbol	NPY2R
Entrez	4887
HUGO	7957
OMIM	162642
RefSeq	NM_000910
UniProt	P49146
Ostali podaci
Lokus	Hromozom 4 q31

Neuropeptidni Y receptor Y1
Neuropeptidni Y receptor Y1
Identifikatori
Simbol	NPY1R
Alt. simboli	NPYR
Entrez	4886
HUGO	7956
OMIM	162641
RefSeq	NM_000909
UniProt	P25929
Ostali podaci
Lokus	Hromozom 4 q31.3-q32

Neuropeptidni Y receptor Y5
Identifikatori
Simbol	NPY5R
Entrez	4889
HUGO	7958
OMIM	602001
RefSeq	NM_006174
UniProt	Q15761
Ostali podaci
Lokus	Hromozom 4 q31-q32

Neuropeptidni Y receptori su klasa G-protein spregnutih receptora koje aktiviraju peptidni hormoni neuropeptid Y, peptid YY i pankreasni polipeptid.^[1] Ovi receptori učestvuju u kontroli raznovrsnog seta of procesa ponašanja, koji obuhvata apetit, cirkadijalni ritam, i anksioznost.^[2]^[3]^[4]^[5]^[6]^[7]

Aktivirani neuropeptidni receptori oslobađaju G_i podjedinicu iz heterotrimernog G proteinskog kompleksa. G_i podjedinica zatim inhibira produkciju sekundarnog glasnika cAMP iz ATP.

Tipovi

Poznata su četiri neuropeptid Y receptora kod sisara. Oni se označavaju sa: Y₁ do Y₅.^[8] Svaki od ovih receptora je kodiran zasebnim genom kod čoveka. Svi oni mogu da budu terapeutski ciljevi za gojaznost i druge poremećaje.^[9]^[10]^[11]

Y₁ - NPY1R
Y₂ - NPY2R
Y₄ - PPYR1
Y₅ - NPY5R

Literatura

^ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (1998). „XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors”. Pharmacol. Rev. 50 (1): 143—50. PMID 9549761.
^ Heilig, M. (2004). „The NPY system in stress, anxiety and depression”. Neuropeptides. 38 (4): 213—24. PMID 15337373. doi:10.1016/j.npep.2004.05.002.
^ Harro, J. (2006). „CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies”. Amino Acids. 31 (3): 215—30. PMID 16738800. doi:10.1007/s00726-006-0334-x.
^ Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry. 7 (17): 1645—59. PMID 17979774. doi:10.2174/156802607782341037. ^{[мртва веза]}
^ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery. 1 (3): 315—24. PMID 18221213. doi:10.2174/157488906778773689. ^{[мртва веза]}
^ Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry. 7 (17): 1710—20. PMID 17979780. doi:10.2174/156802607782340966. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.
^ Lindner D, Stichel J, Beck-Sickinger AG (2008). „Molecular recognition of the NPY hormone family by their receptors”. Nutrition (Burbank, Los Angeles County, Calif.). 24 (9): 907—17. PMID 18725086. doi:10.1016/j.nut.2008.06.025.
^ Larhammar D, Salaneck E (2004). „Molecular evolution of NPY receptor subtypes”. Neuropeptides. 38 (4): 141—51. PMID 15337367. doi:10.1016/j.npep.2004.06.002.
^ Kamiji MM, Inui A (2007). „Neuropeptide y receptor selective ligands in the treatment of obesity”. Endocrine Reviews. 28 (6): 664—84. PMID 17785427. doi:10.1210/er.2007-0003.
^ MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry. 7 (17): 1721—33. PMID 17979781. doi:10.2174/156802607782341028. Архивирано из оригинала 12. 01. 2013. г. Приступљено 09. 10. 2018.
^ Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry. 7 (17): 1734—42. PMID 17979782. doi:10.2174/156802607782340957. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.

Spoljašnje veze

„Neuropeptide Y Receptors”. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Архивирано из оригинала 03. 03. 2016. г.
Neuropeptide+Y+Receptor на US National Library of Medicine Medical Subject Headings (MeSH)

[pmid9549761-1] Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (1998). „XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors”. Pharmacol. Rev. 50 (1): 143—50. PMID 9549761.

[pmid15337373-2] Heilig, M. (2004). „The NPY system in stress, anxiety and depression”. Neuropeptides. 38 (4): 213—24. PMID 15337373. doi:10.1016/j.npep.2004.05.002.

[pmid16738800-3] Harro, J. (2006). „CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies”. Amino Acids. 31 (3): 215—30. PMID 16738800. doi:10.1007/s00726-006-0334-x.

[pmid17979774-4] Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry. 7 (17): 1645—59. PMID 17979774. doi:10.2174/156802607782341037. ^{[мртва веза]}

[pmid18221213-5] Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery. 1 (3): 315—24. PMID 18221213. doi:10.2174/157488906778773689. ^{[мртва веза]}

[pmid17979780-6] Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry. 7 (17): 1710—20. PMID 17979780. doi:10.2174/156802607782340966. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.

[pmid18725086-7] Lindner D, Stichel J, Beck-Sickinger AG (2008). „Molecular recognition of the NPY hormone family by their receptors”. Nutrition (Burbank, Los Angeles County, Calif.). 24 (9): 907—17. PMID 18725086. doi:10.1016/j.nut.2008.06.025.

[pmid15337367-8] Larhammar D, Salaneck E (2004). „Molecular evolution of NPY receptor subtypes”. Neuropeptides. 38 (4): 141—51. PMID 15337367. doi:10.1016/j.npep.2004.06.002.

[pmid17785427-9] Kamiji MM, Inui A (2007). „Neuropeptide y receptor selective ligands in the treatment of obesity”. Endocrine Reviews. 28 (6): 664—84. PMID 17785427. doi:10.1210/er.2007-0003.

[pmid17979781-10] MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry. 7 (17): 1721—33. PMID 17979781. doi:10.2174/156802607782341028. Архивирано из оригинала 12. 01. 2013. г. Приступљено 09. 10. 2018.

[pmid17979782-11] Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry. 7 (17): 1734—42. PMID 17979782. doi:10.2174/156802607782340957. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]